RLAY Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.396

-12.03%

-0.429

-6.65%

-0.435

+6.05%

Estimates Revision

The market is revising Downward the revenue expectations for Relay Therapeutics, Inc. (RLAY) for FY2025, with the revenue forecasts being adjusted by -1.56% over the past three months. During the same period, the stock price has changed by 17.85%.

Revenue Estimates for FY2025

Revise Downward

-1.56%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+2.27%

In Past 3 Month

Stock Price

Go Up

+17.85%

In Past 3 Month

6 Analyst Rating

Wall Street analysts forecast RLAY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RLAY is 15.25 USD with a low forecast of 14.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

14.00

Averages

15.25

High

17.00

Current: 0.000

Low

14.00

Averages

15.25

High

17.00

Wells Fargo

Equal Weight -> Overweight

upgrade

$6 -> $13

2025-12-12

Reason

Wells Fargo

Price Target

$6 -> $13

2025-12-12

upgrade

Equal Weight -> Overweight

Reason

Wells Fargo upgraded Relay Therapeutics to Overweight from Equal Weight with a price target of $13, up from $6. The firm believes the stock could work in 2026 on its data updates. Wells expects the RLY-2608 data to be competitive.

Guggenheim

Brad Canino

initiated

$10 -> $15

2025-09-04

Reason

Guggenheim

Brad Canino

Price Target

$10 -> $15

2025-09-04

initiated

Reason

Guggenheim analyst Brad Canino assumed coverage of Relay Therapeutics with a Buy rating and price target of $15, up from $10. The analyst names Relay a "best idea." The firm has high conviction in the company's breast cancer potential and says it could undergo a nearer-term turnaround for the recently initiated development of RLY-2608 for vascular malformations. The company's mutant-selective inhibitor could deliver substantial cross-trial increases in efficacy based, the analyst tells investors in a research note.

Guggenheim

NULL -> Buy

upgrade

$10 -> $15

2025-09-03

Reason

Guggenheim

Price Target

$10 -> $15

2025-09-03

upgrade

NULL -> Buy

Reason

Guggenheim assumed coverage of Relay Therapeutics with a Buy rating and price target of $15, up from $10.

H.C. Wainwright

Robert Burns

Buy

downgrade

$16 -> $14

2025-08-26

Reason

H.C. Wainwright

Robert Burns

Price Target

$16 -> $14

2025-08-26

downgrade

Buy

Reason

H.C. Wainwright analyst Robert Burns lowered the firm's price target on Relay Therapeutics to $14 from $16 and keeps a Buy rating on the shares. The firm updated the company's model post the Q2 report.

Raymond James

Strong Buy

downgrade

$29 -> $19

2025-08-08

Reason

Raymond James

Price Target

$29 -> $19

2025-08-08

downgrade

Strong Buy

Reason

Raymond James lowered the firm's price target on Relay Therapeutics to $19 from $29 and keeps a Strong Buy rating on the shares. Relay Therapeutics reported Q2 results, and OpEx was down 16% quarter over quarter following strategic cost-cutting initiatives, which is meaningful, the analyst tells investors in a research note. The firm does not anticipate a significant increase in burn in the near-term, despite ramping the Phase 3 RLY-2608 study.

HC Wainwright & Co.

Robert Burns

Strong Buy

Reiterates

$16

2025-03-07

Reason

HC Wainwright & Co.

Robert Burns

Price Target

$16

2025-03-07

Reiterates

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Relay Therapeutics Inc (RLAY.O) is -4.85, compared to its 5-year average forward P/E of -6.01. For a more detailed relative valuation and DCF analysis to assess Relay Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.01

Current PE

-4.85

Overvalued PE

-1.61

Undervalued PE

-10.42

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.49

Current EV/EBITDA

-2.89

Overvalued EV/EBITDA

0.23

Undervalued EV/EBITDA

-7.22

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

940.98

Current PS

284.14

Overvalued PS

2205.72

Undervalued PS

-323.76

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 352.49% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

RLAY News & Events

Events Timeline

No data

News

9.0

2025-12-16Newsfilter

Oncolytics Biotech Secures FDA Approval with 33% Efficacy for New Drug

9.0

2025-12-16Globenewswire

Oncolytics Biotech Secures FDA Approval with 33% Efficacy for Pelareorep in Colorectal Cancer

9.0

2025-12-12Benzinga

Relay Therapeutics Announces Strong Efficacy of Targeted Breast Cancer Treatment

People Also Watch

Frequently Asked Questions

What is Relay Therapeutics Inc (RLAY) stock price today?

The current price of RLAY is 7.99 USD — it has decreased -0.13 % in the last trading day.

What is Relay Therapeutics Inc (RLAY)'s business?

Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608. It is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including RLY-2608. RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor in clinical development. It is the lead program in its efforts to discover and develop mutant selective inhibitors of PI3Kα.

What is the price predicton of RLAY Stock?

What is Relay Therapeutics Inc (RLAY)'s revenue for the last quarter?

Relay Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Relay Therapeutics Inc (RLAY)'s earnings per share (EPS) for the last quarter?

Relay Therapeutics Inc. EPS for the last quarter amounts to -0.43 USD, decreased -31.75 % YoY.

What changes have occurred in the market's expectations for Relay Therapeutics Inc (RLAY)'s fundamentals?

How many employees does Relay Therapeutics Inc (RLAY). have?

Relay Therapeutics Inc (RLAY) has 261 emplpoyees as of January 10 2026.

What is Relay Therapeutics Inc (RLAY) market cap?

Today RLAY has the market capitalization of 1.38B USD.